South & Central America T Cell Therapy Market

The South & Central America T cell therapy market was valued at US$ 84.11 million in 2022 and is expected to reach US$ 265.59 million by 2030; it is estimated to grow at a CAGR of 15.5% from 2022 to 2030.

Increasing Number of T-Cell Therapy Approvals Fuels the South & Central America T Cell Therapy Market

Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approval:

•   In 2023: Kite, a Gilead Company announced launching operations in Saudi Arabia, Singapore, and Brazil as part of its commercial expansion. Kite has filed regulatory applications for its CAR T-cell therapy products in each of the three nations.

•   For instance, in June 2022, Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).

•   In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.

•   In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

•   In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.

•   In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.

Therefore, the increasing number of approvals for T-cell therapies is fueling the market growth.

South & Central America T Cell Therapy Market Overview

The South & Central America T-cell therapy market is limited to Brazil as the products are only approved and commercially available in the country. According to the Brazilian Journal of Cancerology, it is estimated that ~704,000 new cases of cancer are expected during 2023–2025. More than 12,000 non-Hodgkin lymphoma (NHL) cases in Brazil are estimated to be diagnosed yearly. The Brazilian Health Regulatory Agency (ANVISA) has approved two CAR T-cell therapies in Brazil: tisagenlecleucel (by Novartis) for pediatric patients and young adults with RR B-cell acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory (RR) diffuse large B-cell lymphoma, and ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM). Moreover, in August 2022, Kite, a Gilead Company, expanded its business by launching operations in Brazil, Singapore, and Saudi Arabia. Kite has submitted regulatory applications for its CAR T-cell therapy products. The rising cases of cancer and lymphoma, and the increasing number of applications and clinical trials for T-cell therapies are expected to boost the demand in the coming years.

South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

South & Central America T Cell Therapy Market Segmentation 

The South & Central America T cell therapy market is segmented into modality, therapy type, indication, and country.

Based on modality, the South & Central America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the South & Central America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the South & Central America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the South & Central America T cell therapy market is limited to Brazil. Brazil dominated the South & Central America T cell therapy market share in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the South & Central America T cell therapy market.

South & Central America T Cell Therapy Market Strategic Insights

South & Central America T Cell Therapy Market Segmentation Analysis

South & Central America T Cell Therapy Market Report Highlights

South & Central America T Cell Therapy Report Scope

South & Central America T Cell Therapy Market Country and Regional Insights